Transition Diary: Deltagen completes Part 1

Deltagen Inc.'s acquisition of Bristol-Myers Squibb Pharma Research Labs L.L.C., formerly CombiChem Inc., which was completed last week, provides the last big piece DGEN needed to complete the first half of its value-added chain through drug discovery. While the company said it is aggressively looking to in-license compounds, and ultimately wants to

Read the full 520 word article

How to gain access

Continue reading with a
two-week free trial.